The FDA has logged a supplemental application action on abrocitinib (Cibinqo, Pfizer, NDA 213871), dated 2 September 2026. Abrocitinib is a selective Janus kinase 1 inhibitor, licensed for atopic dermatitis rather than for any rheumatological indication.
What the supplement covers is not stated in the regulatory record, and it would be wrong to guess. A supplemental application can carry a new indication, an age extension, a manufacturing change, a new formulation or a labelling change including a safety update — these mean quite different things to a prescriber, and only the approval letter and the revised label will say which this is.
The reason it belongs on a rheumatology desk at all is the class. JAK inhibitor labelling has moved as a group before, particularly on cardiovascular and malignancy warnings carried across from the tofacitinib safety trial, and a label change on one JAK inhibitor is worth knowing about even when the drug itself is dermatological. If you prescribe JAK inhibitors for inflammatory arthritis, the action to take is to check the revised Cibinqo label when it posts, and to check whether anything in it has been mirrored onto the products you use. Nothing in this record calls for a change to current prescribing.
- Note the action, do not infer its content — a supplement can be an indication, a formulation or a safety label change
- Check the revised label when it posts on the FDA site before quoting what changed
- Watch for class-wide read-across to JAK inhibitors used in inflammatory arthritis
- Abrocitinib is not licensed for rheumatological indications; this is not a new option for your patients
- CDSCO status and Indian availability for abrocitinib are separate questions this record does not address
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free